Pharmamarketeer

FDA grants Johnson & Johnson’s Invokana new kidney disease approval

Johnson & Johnson’s Invokana (canaglifolozin) has become the only drug in the SGLT2 inhibitor class to be approved by the FDA for treating diabetic kidney disease (DKD) and to reduce the risk of hospitalisation for heart failure in patients with type 2 diabetes and DKD.

read more

Medhc-fases-banner
Advertentie(s)